17,44 €
Lactobacillus reuteri Pylopass®
Category: Probiotics
Manufacturer: Kenay GmbH
An effective and safe probiotic to support immunity and fight infections
- Enhances anti-inflammatory effect and regulates immune response
- Reduces intestinal disorders
- Effectively eliminates Helicobacter pylori
- It is effective against oral infections caused by Candida strains
- Provides support in the case of infections caused by Clostridium difficile
- May reduce infant colic
- Helps maintain the balance of the intestinal microbiome and thus strengthens immunity
- Contains a patented and unique strain of Lactobacillus reuteri (DSM 17648)
- Product suitable for vegetarians (Vcaps® capsule)
In stock
Volume discounts
Quantity | Price | You Save |
---|---|---|
2 | 25,11 € | Up to 2,09 € |
4 | 24,59 € | Up to 6,28 € |
By buying this product you can collect up to 26 loyalty points. Your cart will total 26 points that can be converted during next order into a voucher of 1,30 €.
More info
Lactobacillus reuteri Pylopass®
60 vegetarian capsules
Item Catalog Number: K2448EN
Original product name: Lactobacillus reuteri Pylopass®
Lactobacillus reuteri [DSM 17938]
In the human body, Lactobacillus reuteri occurs, among others, in the digestive tract, urinary tract, skin and mother's milk.[10]
Past few decades, there has been a decrease in the abundance of Lactobacillus reuteri in humans. This is most likely caused by the widespread use of processed food rich in trans fats and sugars, the overuse of antibiotics both by humans and in animal husbandry, and excessive attention to hygiene.[7,10]
Unfortunately, this decline in the abundance of Lactobacillus reuteri is closely correlated with the increasing incidence of inflammatory diseases. Lactobacillus reuteri is a strain that plays a very important role in eliminating infections and alleviating both gastrointestinal diseases and diseases of distant tissues.[10]
The use of Lactobacillus reuteri may be helpful both as a preventive measure and in the case of acute infectious diarrhea, Helicobacter pylori infections, general functional disorders of the digestive tract, as well as caries and infections of the reproductive organs, in irritable bowel syndrome, lactose intolerance, bronchial asthma and recurrent inflammation of the urinary system.[13]
Lactobacillus reuteri [DSM 17938] alleviates intestinal disorders by protecting the intestinal barrier, inhibiting inflammation and supporting the immune response. This strain also helps maintain the balance of intestinal microflora and inhibits oxidative stress.[8]
Many clinical studies prove that the use of Lactobacillus reuteri DSM 17938 can reduce infant colic.[11]
Lactobacillus reuteri produces metabolites that are very beneficial for whole body health. One of them - reuterin is a well-known antimicrobial agent. Reuterin is effective against: E. coli, Salmonella typhimurium, Pseudomonas fluorescens, Shigella spp., Campylobacter jejuni, Strepotococcus mutans, Prevotella intermedia, Bacillus subtilis, Listeria monocytogenes, Clostridium perfringens, Staphylococcus aureus, Helicobacter pylori, Fusobacterium nucleatum, Porphyromonas gingivali s, Candida albicans, Fusarium samiaciens, Aspergillus flavus.[13,14,15]
Apart from reuterin, Lactobacillus reuteri produces other antimicrobial substances, including lactic acid, acetic acid, ethanol, and reutericyclin.[7,10]
What is Pylopass®
Pylopass® is produced by fermenting a patented strain of L. reuteri under controlled conditions to achieve peak aggregation capabilities. After fermentation, the cells are harvested, embedded in a matrix and spray dried at low temperature. Pylopass™ has been tested in numerous clinical trials involving humans.
In the European Union, the Lactobacillus reuteri strain has the status of "qualified presumption of safety" (QPS). In the US, Pylopass™ has also been rated “Generally Recognized as Safe” (GRAS).[4]
Benefits at a Glance:
- Enhances anti-inflammatory effect and regulates immune response
- Reduces intestinal disorders
- Effectively eliminates Helicobacter pylori
- It is effective against oral infections caused by Candida strains
- Provides support in the case of infections caused by Clostridium difficile
- May reduce infant colic
- Helps maintain the balance of the intestinal microbiome and thus strengthens immunity
- Contains a patented and unique strain of Lactobacillus reuteri (DSM 17648)
- Product suitable for vegetarians (Vcaps® capsule)
Lactobacillus reuteri [DSM 17938] and Helicobacter pylori
Helicobacter pylori may cause many gastrointestinal diseases, including stomach ulcers. Helicobacter pylori infection may cause increased gastric acid secretion and gastritis and bacterial non-atrophic gastritis.[3,9]
One in vivo clinical study demonstrated a significant decrease in gastric colonization by Helicobacter pylori after supplementation with Lactobacillus reuteri.[1]
Lactobacillus reuteri supplementation along with the Saccharomyces boulardi in Helicobacter pylori infection effectively eliminates the pathogen without the common side effects accompanying antibiotic therapy.[7]
Lactobacillus reuteri [DSM 17938] and oral cavity infections caused by Candida species
An in vitro study was conducted to investigate the effect of Lactobacillus reuteri on fungal infections in the oral cavity caused by Candida species (C. albicans, C. glabrata, C. krusei, C. tropicalis, C. dubliniensis, and C. parapsilosis).[2]
Lactobacillus reuteri has been shown to have antifungal properties against 5 of the 6 Candida strains tested (C. albicans, C. glabrata, C. tropicalis, C. dubliniensis, and C. parapsilosis).[2]
Lactobacillus reuteri [DSM 17938] and Clostridium difficile infections
In developed countries, Clostridium difficile is the main cause of infectious diarrhea in hospitalized patients.[12]
Infections caused by Clostridium difficile are very difficult to treat due to the antibiotic resistance of this strain.
As shown in one scientific study, one of the metabolites of Lactobacillus reuteri, reuterin, depending on its concentration, interferes with the metabolism of Clostridium difficile by producing reactive oxygen species. [5,12] Sublethal concentrations of reuterin increase the susceptibility of Clostridium difficile to vancomycin and metronidazole.[5,12]
Reuterin inhibits also the growth of some Gram-positive and Gram-negative bacteria, as well as fungi and protozoa.[13]
Supplement Facts
Daily dose: 1 capsule
Amount Per Day (1 capsule) | |
---|---|
Lactobacillus reuteri DSM 17648 [Pylopass®] |
230 mg |
Ingredients: Lactobacillus reuteri; capsule: hydroxypropylmethylcellulose. |
Vcaps® is a trademark of Lonza or its affiliates.
Pylopass® is a registered trademark of Novozymes Berlin GmbH
Dosage and Use
Take one (1) capsule daily with breakfast or as recommended by a healthcare practitioner.
Storage: Store in a closed container at room temperature, out of the reach of small children.
Warnings:
Before you start using any dietary supplement, consult your doctor.
Dietary supplements are not medicines.
Do not exceed the recommended daily dose.
Dietary supplements cannot be used as a substitute for a varied diet.
Do not use in case of hypersensitivity to any ingredient of the preparation.
The product should not be used by pregnant or breastfeeding women and children and adolescents under 3 years of age.
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775242/
- https://pubmed.ncbi.nlm.nih.gov/28326154/
- https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02187-z
- https://www.novozymesonehealth.com/solutions/pylopass
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524292/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471993/
- https://radioklinika.pl/lactobacillus-reuteri-lr-probiotyk/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932687/
- Ford A.C., Axon A.T. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2010;15:1–6. doi: 10.1111/j.1523-5378.2010.00779.x.
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917019/
- https://www.jpeds.com/article/S0022-3476(11)00062-X/fulltext
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806400/
- https://www.sciencedirect.com/science/article/pii/S003139391170511X
- I.A. Casas, W.J. Dobrogosz "Validation of the Probiotic Concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals" Microb Ecol Health Dis, 12 (2000), pp. 247-285
- V. Cleusix, C. Lacroix, S. Vollenweider, G. Le Blay "Glycerol induces reuterin production and decreases Escherichia coli population in an in vitro model of colonic fermentation with immobilized human feces" FEMS Microbiol Ecol, 63 (2008), pp. 56-64